2020-11-06T10:50:29-06:00 2019-12-31 362239746 SASSETTI LLC 6611 NORTH AVENUE OAK PARK IL 60302 990 2019-01-01 272523450 USHER III INITIATIVE INC USHE 3128962509 191 N WACKER DRIVE NO 1790 CHICAGO IL 60606 CYNTHIA ELDEN PRESIDENT 3128962509 2020-11-03 1 JEFF SCHROEDER P01245303 7083861433 2020-11-03 50.249.223.178 2020-11-03 13:11:20 CS P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 4BD8B080C63AFF479F8002C959B23E85A162128F 2019 2021-01-29 14:40:06Z CYNTHIA ELDEN 191 N WACKER DRIVE NO 1790 CHICAGO IL 60606 788460 0 X WWW.USHERIII.ORG X 2010 IL TO IDENTIFY THERAPIES, TREATMENTS AND A CURE FOR USHER SYNDROME TYPE III. 7 7 0 10 0 0 770845 788460 0 0 0 0 0 0 770845 788460 75000 0 0 0 0 0 0 0 3304 492152 838519 567152 838519 203693 -50059 675782 653017 61900 89194 613882 563823 TO ACHIEVE ITS GOAL OF DEVELOPING A TREATMENT TO SLOW OR REVERSE THE VISION LOSS ASSOCIATED WITH USHER III, THE INITIATIVE HAS PURSUED AN APPROACH THAT FOCUSES ON SMALL MOLECULE CHAPERONE THERAPY. 0 0 536314 CONTINUE DEVELOPMENT OF LEAD DRUG COMPOUND TO TREAT USHER SYNDROME TYPE 3, INCLUDING RESEARCH, PRE-CLINICAL SAFETY STUDIES AND MANUFACTURING. 249728 OTHER PROGRAM EXPENSES INCLUDING OVERSIGHT, ADMINISTRATION, EVALUATION AND PATENT REGISTRATION. 786042 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 0 0 0 0 IL X ALICIA DERRAH 3128962509 191 N WACKER DRIVE NO 1790 CHICAGO IL 60606 X CYNTHIA ELDEN PRESIDENT 6.00 X X 0 0 0 MARK ACKERMANN DIRECTOR 1.00 X 0 0 0 DR JULIA HAYES DIRECTOR 1.00 X 0 0 0 JAMES C MURRAY DIRECTOR 1.00 X 0 0 0 DR DAVID SAPERSTEIN DIRECTOR 1.00 X 0 0 0 MICHAEL KRAINES DIRECTOR 1.00 X 0 0 0 DR PAUL STERNBERG JR DIRECTOR 1.00 X 0 0 0 ALICIA DERRAH TREASURER 6.00 X 0 0 0 0 0 0 0 0 0 0 COOLEY LLP 3175 HANOVER STREET PALO ALTO CA 943041130 LEGAL SERVICES 143728 1 788460 788460 788460 0 0 0 X 263599 219130 44469 8800 7315 1485 543583 542129 1454 3474 214 214 3046 10260 10260 TELEPHONE 6994 6994 MISCELLANEOUS 1001 1001 REGISTRATION FEES 550 550 CREDIT CARD FEES 258 258 838519 786042 49173 3304 675782 590959 50000 12058 675782 653017 61900 89194 61900 89194 X 613882 563823 613882 563823 675782 653017 -50059 0 X 0 1 X 0 0 X 375155 314844 331406 770845 788460 2580710 375155 314844 331406 770845 788460 2580710 1968544 612166 2580710 0.23720 0.42110 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 788460 0 788460 0 788460 838519 0 838519 0 838519 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES MEDICAL RESEARCH 467379 0 0 0 0 0 0 467379 0 467379 0 0 0 0 0 0 PART III ACCOUNTING METHOD: FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS MEMBERS. MEMBERS ARE GAIL ELDEN, CINDY ELDEN, AND TOM ELDEN. FORM 990, PART VI, SECTION A, LINE 7A MEMBERS HAVE THE POWER TO ELECT THE GOVERNING BOARD, AND THE POWER TO REMOVE DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B ANY AMENDMENTS TO THE BYLAWS MUST BE APPROVED BY BOTH THE MEMBERS AND DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE TREASURER. A COPY IS PROVIDED TO ALL BOARD MEMBERS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C TO ENSURE THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS CHARITABLE PURPOSE AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE ITS TAX EXEMPT STATUS, PERIODIC REVIEWS SHALL BE CONDUCTED TO DETERMINE WHETHER 1.) COMPENSATION AGREEMENTS AND BENEFITS ARE REASONABLE, AND THAT 2.) ALL OFFICERS AND DIRECTORS FILE ANNUAL CONFLICTS STATEMENTS THAT IS REVIEWED BY THE TREASURER AND LEGAL COUNSEL AND, IF REQUIRED, ESCALATED TO THE BOARD FOR REVIEW. FORM 990, PART VI, SECTION C, LINE 18 COPIES OF FORMS 990 AND 1023 ARE AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER: PROGRAM SERVICE EXPENSES 5,815. MANAGEMENT AND GENERAL EXPENSES 1,454. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 7,269. MEDICAL RESEARCH: PROGRAM SERVICE EXPENSES 536,314. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 536,314.